BMS-184476

BMS-184476 is a synthetic small molecule taxane derivative developed by Bristol Myers Squibb as an antineoplastic agent. It is a 7-methylthiomethyl ether derivative of paclitaxel designed to improve upon the pharmacological and toxicity profile of paclitaxel. BMS-184476 acts by binding to and stabilizing microtubules, thereby inhibiting their depolymerization, which disrupts mitosis and leads to cell death in rapidly dividing tumor cells. The drug was investigated primarily for the treatment of solid tumors, including non-small-cell lung cancer, breast cancer, ovarian cancer, and other advanced malignancies. Clinical trials reached phase II before development was discontinued due to toxicity concerns and lack of sufficient clinical benefit over existing therapies[2][3][4][5][7].

Other names

7-methylthiomethylpaclitaxel